Rafferty Asset Management LLC raised its holdings in Curis, Inc. (NASDAQ:CRIS) by 6.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 325,654 shares of the biotechnology company’s stock after purchasing an additional 20,535 shares during the period. Rafferty Asset Management LLC owned about 0.36% of Curis worth $2,628,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. ClariVest Asset Management LLC acquired a new stake in Curis in the second quarter valued at approximately $837,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Curis in the second quarter worth approximately $55,000. Swiss National Bank acquired a new stake in shares of Curis in the second quarter worth approximately $1,215,000. Rhumbline Advisers acquired a new stake in shares of Curis in the second quarter worth approximately $672,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Curis in the second quarter worth approximately $155,000. 88.55% of the stock is currently owned by institutional investors.
CRIS has been the topic of a number of research analyst reports. Zacks Investment Research lowered Curis from a “hold” rating to a “sell” rating in a research note on Tuesday, August 3rd. B. Riley reaffirmed a “buy” rating and issued a $22.00 price target on shares of Curis in a research note on Wednesday, August 4th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Curis in a research note on Monday, June 14th. Finally, TheStreet lowered Curis from a “c-” rating to a “d” rating in a research note on Thursday, June 17th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, Curis has a consensus rating of “Buy” and an average price target of $19.20.
Curis (NASDAQ:CRIS) last released its quarterly earnings data on Monday, August 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.01). The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.33 million. Curis had a negative return on equity of 40.73% and a negative net margin of 334.50%. On average, equities research analysts predict that Curis, Inc. will post -0.49 earnings per share for the current fiscal year.
Curis Company Profile
Curis, Inc engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.
Recommended Story: Why are percentage gainers important?
Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS).
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.